Kristi A. Boehm

3.1k total citations
77 papers, 2.3k citations indexed

About

Kristi A. Boehm is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Kristi A. Boehm has authored 77 papers receiving a total of 2.3k indexed citations (citations by other indexed papers that have themselves been cited), including 45 papers in Oncology, 38 papers in Pulmonary and Respiratory Medicine and 12 papers in Cancer Research. Recurrent topics in Kristi A. Boehm's work include Cancer Treatment and Pharmacology (23 papers), Colorectal Cancer Treatments and Studies (20 papers) and Lung Cancer Treatments and Mutations (16 papers). Kristi A. Boehm is often cited by papers focused on Cancer Treatment and Pharmacology (23 papers), Colorectal Cancer Treatments and Studies (20 papers) and Lung Cancer Treatments and Mutations (16 papers). Kristi A. Boehm collaborates with scholars based in United States. Kristi A. Boehm's co-authors include Lina Asmar, Donald Richards, Svetislava J. Vukelja, William Hyman, Joanne L. Blum, John F. Sandbach, Kristi McIntyre, Frankie A. Holmes, Michael A. Savin and Robert Kirby and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer.

In The Last Decade

Kristi A. Boehm

75 papers receiving 2.3k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Kristi A. Boehm United States	24	1.5k	736	720	495	309	77	2.3k
Giuseppe Capri Italy	27	2.1k 1.4×	453 0.6×	717 1.0×	555 1.1×	233 0.8×	77	2.8k
Teresa Gamucci Italy	28	2.3k 1.6×	688 0.9×	723 1.0×	827 1.7×	155 0.5×	128	3.5k
Roger Keresztes United States	19	1.1k 0.8×	631 0.9×	456 0.6×	655 1.3×	203 0.7×	37	2.7k
Massimo Lopez Italy	21	1.6k 1.1×	598 0.8×	516 0.7×	405 0.8×	213 0.7×	59	2.2k
Ioannis A. Voutsadakis Canada	27	1.2k 0.8×	474 0.6×	639 0.9×	914 1.8×	298 1.0×	161	2.3k
Jean Charles Soria France	25	1.2k 0.8×	965 1.3×	561 0.8×	1.5k 2.9×	301 1.0×	48	3.1k
J. L. Misset France	27	2.1k 1.5×	1.0k 1.4×	566 0.8×	433 0.9×	438 1.4×	63	3.0k
David Chu United States	27	1.1k 0.7×	674 0.9×	428 0.6×	1.1k 2.2×	171 0.6×	56	2.8k
Edgar Petru Austria	33	1.5k 1.0×	898 1.2×	897 1.2×	691 1.4×	378 1.2×	222	3.9k
O. Kisker Germany	28	2.0k 1.4×	876 1.2×	620 0.9×	988 2.0×	376 1.2×	43	3.3k

Countries citing papers authored by Kristi A. Boehm

Since Specialization

Citations

This map shows the geographic impact of Kristi A. Boehm's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kristi A. Boehm with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kristi A. Boehm more than expected).

Fields of papers citing papers by Kristi A. Boehm

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kristi A. Boehm. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kristi A. Boehm. The network helps show where Kristi A. Boehm may publish in the future.

Co-authorship network of co-authors of Kristi A. Boehm

This figure shows the co-authorship network connecting the top 25 collaborators of Kristi A. Boehm. A scholar is included among the top collaborators of Kristi A. Boehm based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kristi A. Boehm. Kristi A. Boehm is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Gelhorn, Heather L., Matthew H. Kulke, Thomas M. O’Dorisio, et al.. (2016). Patient-reported Symptom Experiences in Patients With Carcinoid Syndrome After Participation in a Study of Telotristat Etiprate: A Qualitative Interview Approach. Clinical Therapeutics. 38(4). 759–768. 38 indexed citations

Reynolds, Craig H., et al.. (2013). Sunitinib malate in previously untreated, nonsquamous, non-small cell lung cancer patients over the age of 70 years: Results of a Phase II trial. Investigational New Drugs. 31(5). 1330–1338. 12 indexed citations

Zambrowicz, Brian, Ike Ogbaa, Kenny Frazier, et al.. (2013). Effects of LX4211, a Dual Sodium-Dependent Glucose Cotransporters 1 and 2 Inhibitor, on Postprandial Glucose, Insulin, Glucagon-like Peptide 1, and Peptide Tyrosine Tyrosine in a Dose-Timing Study in Healthy Subjects. Clinical Therapeutics. 35(8). 1162–1173.e8. 52 indexed citations

Saltz, Leonard B., Suprith Badarinath, Shaker R. Dakhil, et al.. (2011). Phase III Trial of Cetuximab, Bevacizumab, and 5-Fluorouracil/Leucovorin vs. FOLFOX-Bevacizumab in Colorectal Cancer. Clinical Colorectal Cancer. 11(2). 101–111. 58 indexed citations

Jones, Stephen E., Frankie A. Holmes, Joyce O’Shaughnessy, et al.. (2009). Docetaxel With Cyclophosphamide Is Associated With an Overall Survival Benefit Compared With Doxorubicin and Cyclophosphamide: 7-Year Follow-Up of US Oncology Research Trial 9735. Journal of Clinical Oncology. 27(8). 1177–1183. 400 indexed citations

Sonpavde, Guru, Phillip Periman, Douglas Weckstein, et al.. (2009). Sunitinib malate for metastatic castration-resistant prostate cancer following docetaxel-based chemotherapy. Annals of Oncology. 21(2). 319–324. 115 indexed citations

Reynolds, Craig H., Robert M. Jotte, Alexander I. Spira, et al.. (2009). Phase II Trial of Nanoparticle Albumin-Bound Paclitaxel, Carboplatin, and Bevacizumab in First-line Patients with Advanced Nonsquamous Non-small Cell Lung Cancer. Journal of Thoracic Oncology. 4(12). 1537–1543. 46 indexed citations

Carter, Dennis L., Lina Asmar, Mark Allen O’Rourke, et al.. (2008). Favorable survival observed after carboplatin, paclitaxel, and concurrent accelerated hyperfractionated radiotherapy for treatment of locally advanced head and neck carcinoma. Investigational New Drugs. 26(5). 473–481. 6 indexed citations

Loesch, David, Lina Asmar, Kristi McIntyre, et al.. (2008). Phase II Trial of Gemcitabine/Carboplatin (plus Trastuzumab in HER2-Positive Disease) in Patients with Metastatic Breast Cancer. Clinical Breast Cancer. 8(2). 178–186. 24 indexed citations

10.

Sonpavde, Guru, Thomas E. Hutson, William R. Berry, Kristi A. Boehm, & Lina Asmar. (2008). Phase II Trial of Sunitinib for the Therapy of Progressive Metastatic Castration-Refractory Prostate Cancer After Previous Docetaxel Chemotherapy. Clinical Genitourinary Cancer. 6(2). 134–137. 8 indexed citations

11.

Sonpavde, Guru, Ana M. Aparicio, Kristi A. Boehm, et al.. (2007). Phase II Study of Azacitidine to Restore Responsiveness of Prostate Cancer to Hormonal Therapy. Clinical Genitourinary Cancer. 5(7). 457–459. 11 indexed citations

12.

Reynolds, Craig H., Paul Conkling, Donald Richards, et al.. (2007). P2-292: A randomized Phase 3 trial of gemcitabine with or without carboplatin in performance status 2 (PS2) patients with advanced (stage IIIB with pleural effusion or IV) non-small-cell lung cancer (NSCLC). Journal of Thoracic Oncology. 2(8). S688–S688. 3 indexed citations

13.

Berry, William R., et al.. (2006). A Phase II Study of Weekly Paclitaxel/Estramustine/Carboplatin in Hormone-Refractory Prostate Cancer. Clinical Genitourinary Cancer. 5(2). 131–137. 19 indexed citations

14.

Blum, Joanne L., Elizabeth Claire Dees, Judith O. Hopkins, et al.. (2006). Phase II Trial of Capecitabine and Weekly Paclitaxel As First-Line Therapy for Metastatic Breast Cancer. Journal of Clinical Oncology. 24(27). 4384–4390. 55 indexed citations

15.

Berry, William R., et al.. (2006). Phase II Study of Low-Dose Docetaxel/Estramustine in Elderly Patients or Patients Aged 18-74 Years with Hormone-Refractory Prostate Cancer. Clinical Genitourinary Cancer. 5(3). 212–218. 3 indexed citations

16.

Richards, Donald, Lalan S. Wilfong, David McCollum, et al.. (2006). Phase II multicenter trial of docetaxel+oxaliplatin in stage IV gastroesophageal and/or stomach cancer. Journal of Clinical Oncology. 24(18_suppl). 4071–4071. 6 indexed citations

17.

Richards, David, Kristi A. Boehm, David Waterhouse, et al.. (2006). Gemcitabine plus CI-994 offers no advantage over gemcitabine alone in the treatment of patients with advanced pancreatic cancer: results of a phase II randomized, double-blind, placebo-controlled, multicenter study. Annals of Oncology. 17(7). 1096–1102. 88 indexed citations

18.

Marsland, Thomas, et al.. (2004). Sequential versus concurrent paclitaxel and carboplatin for the treatment of advanced non-small cell lung cancer in elderly patients and patients with poor performance status: results of two Phase II, multicenter trials. Lung Cancer. 47(1). 111–120. 23 indexed citations

19.

Boehm, Kristi A., et al.. (1992). Prefilter and Postfilter Cysteine/Cystine and Copper Concentrations in Pediatric Parenteral Nutrition Solutions. Journal of Parenteral and Enteral Nutrition. 16(5). 460–463. 7 indexed citations

20.

Boehm, Kristi A.. (1960). [The flavonoids. Part 4].. PubMed. 10. 54–8. 23 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact